Leadership Overview
Alkermes has 4 executives leading key functions including strategic leadership, research and development, human capital management, and legal compliance.
Focused on advancing neuroscience through patient-inspired science, Alkermes delivers innovative medicines for complex psychiatric and neurological disorders while addressing critical unmet medical needs across global markets.
Focused on advancing neuroscience through patient-inspired science, Alkermes delivers innovative medicines for complex psychiatric and neurological disorders while addressing critical unmet medical needs across global markets.
Leadership Roles at Alkermes
Blair Jackson - Chief Executive Officer, Elect
Blair Jackson, the Chief Executive Officer, Elect at Alkermes, directs the overarching strategic vision for the global biopharmaceutical enterprise. Jackson architects long-term growth initiatives while overseeing the transition of leadership to ensure continuity in the development of medicines for psychiatric and neurological disorders. By aligning clinical research with commercial infrastructure, the Chief Executive Officer, Elect optimizes the delivery of treatments for conditions like schizophrenia and bipolar disorder. Jackson maintains rigorous oversight of the company's portfolio, ensuring that scientific advancements translate into tangible patient outcomes. Through collaboration with the Board and executive leadership, Blair Jackson drives the organizational mission to address serious unmet medical needs. This leadership role requires constant evaluation of market dynamics and internal operational efficiency. Ultimately, Jackson secures the future trajectory of the company by fostering a culture of innovation and scientific excellence across all international operations.
Craig Hopkinson - Executive Vice President & Chief Marketing Officer, Research & Development
Craig Hopkinson, the Executive Vice President & Chief Marketing Officer, Research & Development at Alkermes, manages the integration of clinical development with commercial strategy. Hopkinson oversees the translation of complex neuroscience research into viable market solutions for addiction and opioid dependence. By bridging the gap between laboratory findings and patient access, the Executive Vice President & Chief Marketing Officer, Research & Development ensures that investigational candidates reach clinical milestones efficiently. Hopkinson coordinates with cross-functional teams to refine the commercial infrastructure supporting the company's marketed medicines. This role involves analyzing global market trends to prioritize therapeutic areas with the highest impact on chronic neurological health. Craig Hopkinson drives the scientific narrative of the organization, ensuring that clinical data effectively informs commercial positioning. Through this dual focus on research and market strategy, Hopkinson strengthens the competitive standing of the enterprise within the global biopharmaceutical landscape.
Stephen Schiavo - Senior Vice President and Chief Human Resources Officer
Stephen Schiavo, the Senior Vice President and Chief Human Resources Officer at Alkermes, directs the talent acquisition and organizational development strategies necessary to support a global biopharmaceutical workforce. Schiavo architects programs that cultivate deep neuroscience expertise, ensuring the company retains top-tier scientific and commercial talent. By aligning human capital initiatives with the broader mission of treating psychiatric and neurological disorders, the Senior Vice President and Chief Human Resources Officer fosters an environment of innovation and operational excellence. Schiavo manages performance frameworks that drive productivity across research, clinical development, and commercial departments. This leadership role involves shaping corporate culture to support the delivery of patient-inspired science. Stephen Schiavo ensures that the organizational structure remains agile enough to respond to evolving medical needs and market challenges. Through strategic workforce planning, Schiavo supports the long-term sustainability and growth of the enterprise, enabling the company to maintain its focus on complex central nervous system diseases.
David Gaffin - Senior Vice President, Chief Legal Officer and Chief Compliance Officer, Alkermes, Inc.
David Gaffin, the Senior Vice President, Chief Legal Officer and Chief Compliance Officer, Alkermes, Inc. at Alkermes, manages the legal framework and regulatory integrity of the global biopharmaceutical enterprise. Gaffin architects robust compliance programs that govern clinical research, drug development, and commercialization activities. By overseeing legal risk management, the Senior Vice President, Chief Legal Officer and Chief Compliance Officer, Alkermes, Inc. ensures that all operations adhere to international standards for pharmaceutical conduct. Gaffin provides critical guidance on intellectual property and corporate governance, protecting the company's investments in innovative medicines for psychiatric and neurological disorders. This role involves constant interaction with regulatory bodies to facilitate the approval and distribution of treatments for conditions like addiction and schizophrenia. David Gaffin drives the ethical standards of the organization, ensuring that every business decision aligns with legal requirements and patient safety. Through meticulous oversight, Gaffin secures the operational foundation required for the company to address serious unmet medical needs.
Explore Leadership Teams in Manufacturing
AbbVie Inc. is a global biopharmaceutical company dedicated to discovering, developing, and delivering innovative medicines and health solutions that address some of the worlds most complex medical challenges. Headquartered in North Chicago, Illinois, the company operates internationally and focuses on advancing treatments that improve patient outcomes and overall quality of life. AbbVies scientific and commercial efforts are concentrated in several core therapeutic areas, including immunology, oncology, neuroscience, eye care, and medical aesthetics, along with other specialty areas where significant unmet medical needs exist. Through these focus areas, the company works to create therapies that help patients manage chronic, serious, and often life-altering diseases.
Company Leadership MS
Founded in 1949 and Headquartered in Mumbai, India, Ipca Laboratories Limited (IPCA) is a fully integrated pharmaceutical company manufacturing and marketing over 350 formulations and 80 API's covering various therapeutic segments.
Company Leadership AP
SM
SN
Eris Lifesciences Ltd is a prominent Indian pharmaceutical company specializing in branded formulations, particularly in the cardio-metabolic sector. The company offers a diverse range of products across various therapeutic areas including anti-diabetes, cardiovascular health, dermatology, and gynecology. Eris is committed to improving patient care through innovative initiatives and pioneering studies aimed at chronic lifestyle-related diseases. Their target clients include healthcare professionals and patients across India, with a focus on enhancing health outcomes.
Company Leadership GA
MM
VK
OneSource Specialty Pharma Limited is a multimodal specialty pharmaceutical contract development and manufacturing organization headquartered in Bengaluru, India. Formed through the merger of three CDMO businesses within the Strides Group, specifically Stelis Biopharma's Biologics CDMO, SteriScience's Complex Injectables, and Strides' Soft Gelatin businesses, OneSource was officially launched at CPHI Milan in 2024. The company operates five state-of-the-art manufacturing facilities in Bengaluru, all approved by major regulatory bodies including the US FDA, European Union authorities, and the Therapeutic Goods Administration. With over 30 years of manufacturing and quality excellence, OneSource employs more than 1,200 professionals, including over 200 techno-commercial experts, and serves more than 50 global pharmaceutical and biotechnology clients. The company specializes in end-to-end capabilities across multiple technology platforms and therapeutic modalities, including biologics drug substance and drug product manufacturing, drug-device combinations such as prefilled syringes and autoinjectors, complex sterile injectables, and soft gelatin capsules. OneSource has the capacity to produce over 100 million injectable doses and 2.4 billion soft gelatin capsules annually, with its flagship Bangalore site being one of the few facilities globally capable of manufacturing both biologics drug substance and drug product on the same premises. The company holds 35 approved Abbreviated New Drug Applications and has 19 commercialized drug products in the United States. Led by CEO Neeraj Sharma and Chief Quality Officer Bernhard Thurnbauer, OneSource is positioned to capitalize on growing demand for GLP-1 drug-device combinations and supply chain diversification driven by the BIOSECURE Act, projecting 32 percent revenue growth in 2025 with sales expected to reach 400 million dollars by 2028.
Company Leadership NS
SN
BM
Frequently Asked Questions Regarding Alkermes Top Executives and Leadership Team
